source
- Roche touts strong Phase 3 track record while trimming pipeline amid peer setbacksRoche's chief executive Thomas Schinecker highlighted the company's high success rate in Phase 3 trials, positioning it as a competitive advantage. The comment accompanied an announcement that Roc…
- Georgiamune sells solid tumor drug to Italy's Menarini for up to $1.1BA small Maryland biotech is shipping a preclinical cancer drug to a family-owned Italian pharma in a deal worth up to $1.1 billion if all goes according to plan, the companies exclusively told Endp…Endpoints · 42m ago↗ source
- GSK and Ionis receive FDA nod for hepatitis B therapy promising functional cure